Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Olfactory Identification among Various Subtypes of Parkinson Disease.

Jalali MM, Roudbary SA, Gerami H, Soleimani R, Ebrahimi SM.

Eur Neurol. 2019 Jul 10:1-7. doi: 10.1159/000501551. [Epub ahead of print]

PMID:
31291631
2.

PTENα regulates endocytosis and modulates olfactory function.

Yuan Y, Zhao X, Wang P, Mei F, Zhou J, Jin Y, McNutt MA, Yin Y.

FASEB J. 2019 Jul 10:fj201900588RR. doi: 10.1096/fj.201900588RR. [Epub ahead of print]

PMID:
31291551
3.

The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease.

Moosa S, Martínez-Fernández R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS.

Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27779. [Epub ahead of print] Review.

PMID:
31291491
4.

Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.

Evers LJW, Krijthe JH, Meinders MJ, Bloem BR, Heskes TM.

Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27790. [Epub ahead of print]

PMID:
31291488
5.

The locus coeruleus: Another vulnerability target in Parkinson's disease.

Oertel WH, Henrich MT, Janzen A, Geibl FF.

Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27785. [Epub ahead of print] No abstract available.

PMID:
31291485
6.

Accurate and affordable assessment of physiological and pathological tremor in rodents with the accelerometer of a smartphone.

Carlsen EMM, Amrutkar DV, Nielsen KS, Perrier JF.

J Neurophysiol. 2019 Jul 10. doi: 10.1152/jn.00281.2019. [Epub ahead of print]

PMID:
31291169
7.

Dopaminergic modulation of motor network compensatory mechanisms in Parkinson's disease.

Jastrzębowska MA, Marquis R, Melie-García L, Lutti A, Kherif F, Herzog MH, Draganski B.

Hum Brain Mapp. 2019 Jul 10. doi: 10.1002/hbm.24710. [Epub ahead of print]

PMID:
31291039
8.

Task-induced functional brain connectivity mediates the relationship between striatal D2/3 receptors and working memory.

Nour MM, Dahoun T, McCutcheon RA, Adams RA, Wall MB, Howes OD.

Elife. 2019 Jul 10;8. pii: e45045. doi: 10.7554/eLife.45045.

9.

Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease.

Tang S, Wang A, Yan X, Chu L, Yang X, Song Y, Sun K, Yu X, Liu R, Wu Z, Xue P.

Drug Deliv. 2019 Dec;26(1):700-707. doi: 10.1080/10717544.2019.1636420.

PMID:
31290705
10.

New perspectives in iron chelation therapy for the treatment of Parkinson's disease.

Nunez MT, Chana-Cuevas P.

Neural Regen Res. 2019 Nov;14(11):1905-1906. doi: 10.4103/1673-5374.259614. No abstract available.

11.

The challenge of pain in the pharmacological management of Parkinson's disease.

Jost WH, Buhmann C.

Expert Opin Pharmacother. 2019 Jul 10:1-8. doi: 10.1080/14656566.2019.1639672. [Epub ahead of print]

PMID:
31290336
12.

Usual walking and obstacle avoidance are influenced by depressive and anxiety symptoms in patients with Parkinson's disease.

Nóbrega-Sousa P, Orcioli-Silva D, Lirani-Silva E, Beretta VS, Vitório R, Gobbi LTB.

Geriatr Gerontol Int. 2019 Jul 9. doi: 10.1111/ggi.13731. [Epub ahead of print]

PMID:
31290261
13.

Correction to: Transcranial Magneto-Acoustic Stimulation Improves Neuroplasticity in Hippocampus of Parkinson's Disease Model Mice.

Wang Y, Feng L, Liu S, Zhou X, Yin T, Liu Z, Yang Z.

Neurotherapeutics. 2019 Jul 9. doi: 10.1007/s13311-019-00760-1. [Epub ahead of print]

PMID:
31290089
14.

Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes.

Allan LM.

Curr Treat Options Neurol. 2019 Jul 10;21(8):38. doi: 10.1007/s11940-019-0581-2. Review.

PMID:
31290049
15.

Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study.

Miki Y, Foti SC, Asi YT, Tsushima E, Quinn N, Ling H, Holton JL.

Brain. 2019 Jul 9. pii: awz189. doi: 10.1093/brain/awz189. [Epub ahead of print]

PMID:
31289815
16.

Role of microtubule-associated protein 6 glycosylated with Gal-(β-1,3)-GalNAc in Parkinson's disease.

Ma L, Song J, Sun X, Ding W, Fan K, Qi M, Xu Y, Zhang W.

Aging (Albany NY). 2019 Jul 9;11. doi: 10.18632/aging.102072. [Epub ahead of print]

17.

Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications.

Lenka A, Pagonabarraga J, Pal PK, Bejr-Kasem H, Kulisvesky J.

Neurology. 2019 Jul 9. pii: 10.1212/WNL.0000000000007913. doi: 10.1212/WNL.0000000000007913. [Epub ahead of print] Review.

PMID:
31289146
18.

Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease.

Lee MJ, Pak K, Kim JH, Kim YJ, Yoon J, Lee J, Lyoo CH, Park HJ, Lee JH, Jung NY.

Neurology. 2019 Jul 9. pii: 10.1212/WNL.0000000000007939. doi: 10.1212/WNL.0000000000007939. [Epub ahead of print]

PMID:
31289143
19.

Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?

Farfel-Becker T, Do J, Tayebi N, Sidransky E.

Trends Neurosci. 2019 Jul 6. pii: S0166-2236(19)30092-X. doi: 10.1016/j.tins.2019.05.010. [Epub ahead of print] Review.

PMID:
31288942
20.

Palliative care for persons with Parkinson's disease: a qualitative study on the experiences of health care professionals.

Lennaerts H, Steppe M, Munneke M, Meinders MJ, van der Steen JT, Van den Brand M, van Amelsvoort D, Vissers K, Bloem BR, Groot M.

BMC Palliat Care. 2019 Jul 9;18(1):53. doi: 10.1186/s12904-019-0441-6.

Supplemental Content

Loading ...
Support Center